Cabaletta Bio, Inc. (CABA)

12,78 -1,26 (-8,97%) Alla chiusura: 4:00PM EST

Cabaletta Bio, Inc.

2929 Arch Street
Suite 600
Philadelphia, PA 19104
United States
267 759 3100
http://www.cabalettabio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 31

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Steven A. Nichtberger	Co-Founder, Chairman, CEO & Pres	782,16k	N/D	1961
Mr. Anup Marda M.B.A.	Chief Financial Officer	548,2k	N/D	1977
Dr. Gwendolyn K. Binder	Exec. VP of Science & Technology	582,89k	N/D	1975
Dr. Michael C. Milone M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/D	N/D	N/D
Dr. Aimee Payne M.D., Ph.D.	Co-Founder & Co-Chair of Scientific Advisory Board	N/D	N/D	N/D
Mr. J. Brian Stalter J.D.	Gen. Counsel	N/D	N/D	1972
Ms. Martha O'Connor	Chief HR Officer	N/D	N/D	N/D
Dr. David J. Chang M.D., M.P.H.	Chief Medical Officer	N/D	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2019 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Cabaletta Bio, Inc. al 22 gennaio 2021 è 10. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.